Since immune checkpoint inhibitors (ICIs) have been a prominent topic in cancer treatment, the expression of eight ICIs (LAG3, HAVCR2, CD27, TNFRSF14, CTLA4, TMIGD2, TIGIT, and PDCD1LG2) were analyzed between groups in the study. Here, TMIGD2 is linked to cancer.